Compare Schwab US Dividend Equity ETF (SCHD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Dividend Equity ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Schwab US Dividend Equity ETF trades at $33.99 (market cap $111.61B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Schwab US Dividend Equity ETF is far larger — about 22.9× Travere Therapeutics Inc. Common Stock's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Dividend Equity ETF for 64 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SCHD | TVTX | |
|---|---|---|
Market Cap | $111.61B | $4.88B |
Volume | 22,238,193 | 1,668,577 |
Sector | Broad Market / Factor | Health |
52-Week High | $35.21 | $67.52 |
52-Week Low | $26.44 | $26.79 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
